Our Pipeline

Using our proprietary drug discovery platform, we are developing a pipeline of first in class precision therapeutics that regulate key muscle proteins to address a broad array of genetically characterized muscle disorders. We have retained global development and commercialization rights to all of our programs. Our current pipeline is summarized below.

Program

Indication

Preclinical

Phase 1

Phase 2

Phase 3

EDG-5506

Myosin ATPase

BMD

Preclinical

Phase 1

Phase 2

Phase 3


EDG-5506*

Myosin ATPase

DMD

Preclinical

Phase 1

Phase 2

Phase 3


EDG-5506*

Myosin ATPase

LGMD, McArdle

Preclinical

Phase 1

Phase 2

Phase 3


EDG-002

Undisclosed Target

HFpEF, HCM

Preclinical

Phase 1

Phase 2

Phase 3


DMD - Duchenne muscular dystrophy
BMD - Becker muscular dystrophy
HCM - Hypertrophic cardiomyopathy
HFpEF -  Heart failure with preserved ejection fraction
LGMD - Limb-girdle muscular dystrophy

 

*Phase 2 ready for DMD, LGMD and McArdle based on Phase 1 data in healthy volunteers and adults with BMD.